Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes

Diabetes, Obesity and Metabolism

Volumn 17, Issue 6, 2015, Pages 554-559

  Derosa, G ^a   Franzetti, I ^b   Querci, F ^c   Romano, D ^a   D'Angelo, A ^a   Maffioli, P ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Azienda Ospedaliera S Antonio Abate di Gallarate   (Italy)

^c Ospedale Pesenti Fenaroli   (Italy)

Author keywords

Continuous glucose monitoring system; Glycaemic variability; Insulin detemir; Insulin glargine; Insulin lispro protamine

Indexed keywords

GLUCOSE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD GLUCOSE VARIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SELF MONITORING; TREATMENT OUTCOME; ANALYSIS; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 1; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; MALE; YOUNG ADULT;

EID: 84928418426     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12454     Document Type: Article

References (21)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. Cox DJ, Gonder-Frederick L, Ritterband L, Clarke W, Kovatchev BP. Prediction of severe hypoglycemia. Diabetes Care 2007; 30: 1370-1373.
3. Mavrogiannaki AN, Migdalis IN. Long-acting basal insulin analogs: latest developments and clinical usefulness. Ther Adv Chronic Dis 2012; 3: 249-257.
4. Ocheltree SM, Hompesch M, Wondmagegnehu ET, Morrow L, Win K, Jacober SJ. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. Eur J Endocrinol 2010; 163: 217-223.
5. Tsujino D, Nishimura R, Morimoto A, Tajima N, Utsunomiya K. A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN). Diabetes Technol Ther 2012; 14: 596-601.
6. Rydén L, Standl E, Bartnik M etal. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
7. Lichtenstein AH, Appel LJ, Brands M etal. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol 2006; 26: 2186-2191.
8. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978; 200: 21-27.
9. Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia 1972; 8: 342-348.
10. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970; 19: 644-655.
11. Zhou J, Li H, Ran X etal. Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring. Med Sci Monit 2011; 17: CR9-CR13.
12. Winer BJ. Statistical Principles in Experimental Design. 2nd edn. New York: McGraw-Hill, 1971.
13. Korsatko S, Glettler K, Olsen KJ etal. A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. Diabetes Obes Metab 2013; 15: 241-245.
14. Abe S, Inoue G, Yamada S etal. Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring. Diabetes Metab Syndr Obes 2011; 4: 283-288.
15. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-416.
16. Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clin Ther 2009; 31: 2086-2097.
17. Pieber TR, Treichel HC, Hompesch B etal. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med 2007; 24: 635-642.
18. Hollander P, Cooper J, Bregnhøj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008; 30: 1976-1987.
19. Swinnen SG, Dain MP, Aronson R etal. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010; 33: 1176-1178.
20. Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009; 25: 542-548.
21. Arakaki RF, Blevins TC, Wise JK etal. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial. Diabetes Obes Metab 2014; 16: 510-518.